MidTerm Efficacy of Beraprost, an Oral Prostacyclin Analog, in the Treatment of Distal CTEPH: A Case Control Study (original) (raw)

Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue

Heart (British Cardiac Society), 2001

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

Meinhard Kneussl

Journal of the American College of Cardiology, 2002

View PDFchevron_right

Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension : Another Step Forward

Aaron Waxman

View PDFchevron_right

The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management

Charles D Burger

The American journal of managed care, 2016

View PDFchevron_right

Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis

Mohammad Eddama

Journal of Clinical Medicine

View PDFchevron_right

Transition from Prostacyclin Analogue Infusion to Oral Therapy in Patients with Pulmonary Arterial Hypertension: A Five Year Follow-Up

Tahir Jameel

Journal of the American College of Cardiology, 2013

View PDFchevron_right

Transition from prostacyclin analogue infusion to oral therapy in patients with pulmonary arterial hypertension: a 5-year follow-up

Tahir Ahmed

Pulmonary circulation, 2013

View PDFchevron_right

Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database

Charles D Burger

Journal of managed care & specialty pharmacy, 2017

View PDFchevron_right

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing

Michela Boromei

Journal of Clinical Medicine

View PDFchevron_right

Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost

George Cremona

Heart (British Cardiac Society), 1998

View PDFchevron_right

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol)

W. Tomkowski

Annals of Internal …, 1990

View PDFchevron_right

Prostacyclin and its analogues in the treatment of pulmonary hypertension

Andrea Olschewski, Werner Seeger

Pharmacology & Therapeutics, 2004

View PDFchevron_right

Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension

Lucie Clapp

Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension, 2020

View PDFchevron_right

Long-Term Treatment of Pulmonary Arterial Hypertension With Treprostinil: Echocardiographic Evaluation of Efficacy

Annarita Vestri

CHEST Journal, 2003

View PDFchevron_right

Prostacyclin and Iloprost in the Treatment of Primary Pulmonary Hypertension

Christopher McCabe

View PDFchevron_right

Therapeutic Strategies in Pulmonary Arterial Hypertension

R. Poscia

European Cardiology Review, 2012

View PDFchevron_right

Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE1, nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension

Hajimu Kurumatani

Prostaglandins, Leukotrienes and Essential Fatty Acids, 2001

View PDFchevron_right

Role of prostacyclin in pulmonary hypertension

Nura Mohamed

Global Cardiology Science and Practice, 2014

View PDFchevron_right

Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy

wouter jacobs

Journal of Heart and Lung Transplantation, 2009

View PDFchevron_right

Management Of Pulmonary Arterial Hypertension: A Brief Overview

Shatavisa Mukherjee

2017

View PDFchevron_right

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost

Roxana Sulica

Pulmonary Circulation, 2013

View PDFchevron_right

A review of pulmonary arterial hypertension: Part 2: Current and expected treatments

Pieter E Postmus

View PDFchevron_right

Current Pharmacological Treatment of Pulmonary Arterial Hypertension

Paschalis Steiropoulos

Current Clinical Pharmacology, 2008

View PDFchevron_right

Prognostic Factors in Severe Pulmonary Hypertension Patients Who Need Parenteral Prostanoid Therapy: The Impact of Late Referral

Dario Vizza, Alfred Nona, Massimo Mancone, Carlo Iacoboni, Serena Marcon

CHEST Journal, 2011

View PDFchevron_right

Saudi experience in the management of pulmonary arterial hypertension; The outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin

Enas Batubara

Annals of Thoracic Medicine

View PDFchevron_right

Key Articles and Guidelines in the Management of Pulmonary Arterial Hypertension: 2011 Update

Tyree Kiser

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012

View PDFchevron_right

Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension

Werner Seeger

Journal of the American College of Cardiology, 2004

View PDFchevron_right

Perfusion lung scan as a prognostic indicator of response to beraprost sodium in idiopathic pulmonary arterial hypertension

JU NA

Pulmonary Pharmacology & Therapeutics, 2006

View PDFchevron_right

MidTerm Efficacy of Beraprost, an Oral Prostacyclin Analog, in the Treatment of Distal CTEPH: A Case Control Study (original) (raw)

Related papers